Inflexion

We were delighted to recently host our inaugural #Healthcare Symposium, bringing together founders, entrepreneurs and senior leaders from across the sector. The sector sits at an inflection point, supported by considerable capital available for investment and a strong pipeline of businesses with the ambition to grow. It is an encouraging environment, and one that presents a compelling opportunity for those looking to build in the space. Our thanks to everyone who joined us, to our speakers, and to Bain & Company for hosting us at their London office. Read more: https://lnkd.in/ekCZ4yFX #BackingAmbition #AcceleratingGrowth

The best pharmaceutical businesses are not always built on inventing new drugs. Sometimes they are built on getting proven medicines to more of the patients who need them. That is the model behind CNX Therapeutics, a specialty pharmaceutical company focused on improving patient access to essential medicines. It did not exist before 2021, when Inflexion carved it out of US pharma group Sunovion Pharmaceuticals with a single product. Today it spans more than 60 countries, has grown to 25 products, and became the first UK-based pharmaceutical company to earn B Corp status. In the latest episode of Inflexion Point, we mark CNX Therapeutics' fifth anniversary. CNX CEO Guy Clark joins host Tim Smallbone and Inflexion's Christian Fellowes to talk through: 👩⚕️How a thesis first sketched on a napkin became a pan-European platform 🩺 Why so many effective medicines never reach the patients who need them 🔬 The discipline of buy-and-build in a fragmented market 💊 Scaling from 17 people to nearly 70 without losing what made the culture special 🎧 Listen now: https://lnkd.in/e7f6CvFc 🎤See our full catalogue of Inflexion Point stories here: https://lnkd.in/eTfBJc2u

In 2021, CNX Therapeutics was a single product carved out of Sunovion. Today it is a pan-European specialty pharma business, and the pace of that growth is the story. In the latest Inflexion Point, CEO Guy Clark and Inflexion's Christian Fellowes set out how far it has come in five years: 💊From 17 people to nearly 70 💊From one product to a portfolio of 25 💊A presence built across more than 60 countries 💊Five acquisitions closed in four years 💊Revenue more than quadrupled Proof of what focused backing can do in a hard market. 🎧 Listen now: https://lnkd.in/e7f6CvFc

Last year CNX Therapeutics acquired the rights to Sativex 🧬, the world's first cannabis based medicine, developed for multiple sclerosis and bought from Jazz Pharmaceuticals. In the company's own words, it is their most landmark deal to date, and it changed the shape of the business. Where CNX once acquired national products selling in a handful of countries, it now holds a treatment with genuine global potential, with healthcare professionals and potential distributors approaching it from around the world. CEO Guy Clark and Inflexion's Christian Fellowes discuss the deal and what it signals about the company's ambitions in the latest Inflexion Point. 🎧 Listen now: https://lnkd.in/e7f6CvFc

The CNX Therapeutics story🧬🎧 A company that did not exist before 2021 is now a pan European specialty pharma business reaching more than 60 countries. How it got there is the whole story, and this episode covers the lot. In the latest Inflexion Point, CEO Guy Clark and Inflexion's Christian Fellowes cover: 🧬 Carving CNX out of Sunovion and building from a single product 🌍 Acquiring Sativex, the world's first cannabis based medicine, from Jazz Pharmaceuticals 👥 Holding the culture together while growing from 17 people to nearly 70 ♻️ Becoming the first UK pharmaceutical company to achieve B Corp status 🎧 Listen now: https://lnkd.in/e7f6CvFc

Some of the medicines the industry overlooks are the ones patients depend on most. Schizophrenia. Multiple sclerosis. Parkinson's. Chronic conditions where innovation has been slow, and where a small change- a tablet taken once a week instead of three times a day, can reshape a person's daily life. CNX Therapeutics was created in 2021 to give these treatments a home and a route to market. Its model is simple in theory and hard in practice: acquire established brands that larger companies have stopped investing in, apply real commercial and regulatory rigour, and get them to the patients who need them across Europe. Five years on, the platform has moved from small national products to genuine global potential, most recently through the rights to the world's first cannabis based medicine for multiple sclerosis. CEO Guy Clark and Inflexion's Christian Fellowes tell the story in the latest episode of Inflexion Point. 🎧 Listen now: https://lnkd.in/e7f6CvFc